While the antigens associated with immunotherapy mediated regression of RCC are not well defined, previous studies have identified 5T4 (trophoblast glycoprotein, TPBG) as an RCC-associated antigen of therapeutic interest. The gene discussed is TPBG; the disease is renal cell carcinoma.